NCT05650528View on ClinicalTrials.gov

QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

January 24, 2024

Study Completion Date

February 26, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

QG101-23-0 capsules

Single and Multiple Dose for oral

DRUG

Placebo

Single and Multiple Dose for oral

Trial Locations (1)

Unknown

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Amckaus PTY LTD.

INDUSTRY